Monashee Investment Management LLC acquired a new position in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company’s stock, valued at approximately $2,775,000. Lumexa Imaging makes up approximately 1.6% of Monashee Investment Management LLC’s investment portfolio, making the stock its 23rd biggest position. Monashee Investment Management LLC owned 0.16% of Lumexa Imaging at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Seven Grand Managers LLC bought a new position in Lumexa Imaging in the 4th quarter valued at about $11,942,000. Assetmark Inc. bought a new position in Lumexa Imaging in the 4th quarter valued at about $36,000. Goldman Sachs Group Inc. bought a new position in Lumexa Imaging in the 4th quarter valued at about $18,870,000. JPMorgan Chase & Co. bought a new position in Lumexa Imaging in the 4th quarter valued at about $15,954,000. Finally, Geode Capital Management LLC bought a new position in Lumexa Imaging in the 4th quarter valued at about $1,548,000.
Insider Activity at Lumexa Imaging
In other news, Director Brett Brodnax purchased 35,000 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $7.25 per share, with a total value of $253,750.00. Following the completion of the purchase, the director owned 62,027 shares of the company’s stock, valued at $449,695.75. This trade represents a 129.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.70% of the company’s stock.
Lumexa Imaging Stock Performance
Analysts Set New Price Targets
Several research firms have commented on LMRI. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, June 1st. Barclays decreased their target price on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lumexa Imaging presently has an average rating of “Moderate Buy” and an average price target of $16.00.
View Our Latest Research Report on Lumexa Imaging
About Lumexa Imaging
We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).
Featured Articles
- Five stocks we like better than Lumexa Imaging
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding LMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI – Free Report).
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
